301 related articles for article (PubMed ID: 23012366)
1. Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons.
Huelsenbeck SC; Schorr A; Roos WP; Huelsenbeck J; Henninger C; Kaina B; Fritz G
J Biol Chem; 2012 Nov; 287(46):38590-9. PubMed ID: 23012366
[TBL] [Abstract][Full Text] [Related]
2. DNA damage response (DDR) induced by topoisomerase II poisons requires nuclear function of the small GTPase Rac.
Wartlick F; Bopp A; Henninger C; Fritz G
Biochim Biophys Acta; 2013 Dec; 1833(12):3093-3103. PubMed ID: 23999236
[TBL] [Abstract][Full Text] [Related]
3. ERK1/2 signaling plays an important role in topoisomerase II poison-induced G2/M checkpoint activation.
Kolb RH; Greer PM; Cao PT; Cowan KH; Yan Y
PLoS One; 2012; 7(11):e50281. PubMed ID: 23166842
[TBL] [Abstract][Full Text] [Related]
4. Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.
Kumar A; Ehrenshaft M; Tokar EJ; Mason RP; Sinha BK
Biochim Biophys Acta; 2016 Jul; 1860(7):1519-27. PubMed ID: 27095671
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation.
Zhao H; Traganos F; Darzynkiewicz Z
Cell Cycle; 2008 Oct; 7(19):3048-55. PubMed ID: 18802408
[TBL] [Abstract][Full Text] [Related]
6. DNA damage response (DDR) via NKX3.1 expression in prostate cells.
Erbaykent-Tepedelen B; Karamil S; Gonen-Korkmaz C; Korkmaz KS
J Steroid Biochem Mol Biol; 2014 May; 141():26-36. PubMed ID: 24434284
[TBL] [Abstract][Full Text] [Related]
7. Assessment of DNA double-strand breaks and gammaH2AX induced by the topoisomerase II poisons etoposide and mitoxantrone.
Smart DJ; Halicka HD; Schmuck G; Traganos F; Darzynkiewicz Z; Williams GM
Mutat Res; 2008 May; 641(1-2):43-7. PubMed ID: 18423498
[TBL] [Abstract][Full Text] [Related]
8. WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
Christmann M; Tomicic MT; Gestrich C; Roos WP; Bohr VA; Kaina B
DNA Repair (Amst); 2008 Dec; 7(12):1999-2009. PubMed ID: 18805512
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
Aoyama M; Grabowski DR; Dubyak GR; Constantinou AI; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
Biochem J; 1998 Dec; 336 ( Pt 3)(Pt 3):727-33. PubMed ID: 9841887
[TBL] [Abstract][Full Text] [Related]
10. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells.
Deng S; Yan T; Nikolova T; Fuhrmann D; Nemecek A; Gödtel-Armbrust U; Kaina B; Wojnowski L
Br J Pharmacol; 2015 May; 172(9):2246-57. PubMed ID: 25521189
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase poisons differentially activate DNA damage checkpoints through ataxia-telangiectasia mutated-dependent and -independent mechanisms.
Siu WY; Lau A; Arooz T; Chow JP; Ho HT; Poon RY
Mol Cancer Ther; 2004 May; 3(5):621-32. PubMed ID: 15141020
[TBL] [Abstract][Full Text] [Related]
12. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
[TBL] [Abstract][Full Text] [Related]
13. Tirapazamine: a hypoxia-activated topoisomerase II poison.
Peters KB; Brown JM
Cancer Res; 2002 Sep; 62(18):5248-53. PubMed ID: 12234992
[TBL] [Abstract][Full Text] [Related]
14. Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis.
Kurose A; Tanaka T; Huang X; Halicka HD; Traganos F; Dai W; Darzynkiewicz Z
Cytometry A; 2005 Nov; 68(1):1-9. PubMed ID: 16184611
[TBL] [Abstract][Full Text] [Related]
15. Efficient induction of chromosome-type aberrations by topoisomerase II inhibitors closely associated with stabilization of the cleavable complex in cultured fibroblastic cells.
Suzuki H; Ikeda T; Yamagishi T; Nakaike S; Nakane S; Ohsawa M
Mutat Res; 1995 May; 328(2):151-61. PubMed ID: 7739599
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
[TBL] [Abstract][Full Text] [Related]
17. S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function.
Cliby WA; Lewis KA; Lilly KK; Kaufmann SH
J Biol Chem; 2002 Jan; 277(2):1599-606. PubMed ID: 11700302
[TBL] [Abstract][Full Text] [Related]
18. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia.
Willmore E; de Caux S; Sunter NJ; Tilby MJ; Jackson GH; Austin CA; Durkacz BW
Blood; 2004 Jun; 103(12):4659-65. PubMed ID: 15010369
[TBL] [Abstract][Full Text] [Related]
19. Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide.
Damrot J; Nübel T; Epe B; Roos WP; Kaina B; Fritz G
Br J Pharmacol; 2006 Dec; 149(8):988-97. PubMed ID: 17088865
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of topoisomerase IIα and induction of DNA damage in cholangiocarcinoma cells by altholactone and its halogenated benzoate derivatives.
Kitdumrongthum S; Reabroi S; Suksen K; Tuchinda P; Munyoo B; Mahalapbutr P; Rungrotmongkol T; Ounjai P; Chairoungdua A
Biomed Pharmacother; 2020 Jul; 127():110149. PubMed ID: 32344256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
